Cell-cycle dysregulation and anticancer therapy

Cell-cycle dysregulation is a hallmark of tumor cells. The ability of normal cells to undergo cell-cycle arrest after damage to DNA is crucial for the maintenance of genomic integrity. The biochemical pathways that stop the cell cycle in response to cellular stressors are called checkpoints. Defecti...

Full description

Saved in:
Bibliographic Details
Published in:Trends in pharmacological sciences (Regular ed.) 2003-03, Vol.24 (3), p.139-145
Main Authors: Stewart, Zoe A, Westfall, Matthew D, Pietenpol, Jennifer A
Format: Article
Language:English
Subjects:
Antineoplastic Agents - pharmacokinetics
Antineoplastic Agents - therapeutic use
Biopharmaceutics - trends
Genes, cdc - drug effects
Humans
Neoplasms - drug therapy
Spindle Apparatus - drug effects
Spindle Apparatus - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cell-cycle dysregulation is a hallmark of tumor cells. The ability of normal cells to undergo cell-cycle arrest after damage to DNA is crucial for the maintenance of genomic integrity. The biochemical pathways that stop the cell cycle in response to cellular stressors are called checkpoints. Defective checkpoint function results in genetic modifications that contribute to tumorigenesis. The regulation of checkpoint signaling also has important clinical implications because the abrogation of checkpoint function can alter the sensitivity of tumor cells to chemotherapeutics. Here, we provide an overview of the mechanisms that regulate the cell cycle, current anticancer therapies that target checkpoint signaling pathways, and strategies for the development of novel chemotherapeutic agents.
ISSN:0165-6147
1873-3735
DOI:10.1016/S0165-6147(03)00026-9